Neurimmune enrols patient in NI006 trial for ATTR cadiomyopathy
The company intends to analyse the safety, tolerability of NI006 in patients with ATTR. Credit: Pexels from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
